Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion

Authors: Meiou Dai, Amal A. Al-Odaini, Ani Arakelian, Shafaat A. Rabbani, Suhad Ali, Jean-Jacques Lebrun

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

After publication of this work [1] an error was noticed in Fig. 3b. The tubulin Western blot control was accidentally used for both SCP2 and SCP25 cells. The corrected figure is shown below. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.
Literature
1.
go back to reference Dai M, et al. A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion. Breast Cancer Res. 2012;14(5):R127.CrossRefPubMedPubMedCentral Dai M, et al. A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion. Breast Cancer Res. 2012;14(5):R127.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
Authors
Meiou Dai
Amal A. Al-Odaini
Ani Arakelian
Shafaat A. Rabbani
Suhad Ali
Jean-Jacques Lebrun
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0832-7

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine